N@N

SYKE, AWRE, SNTS, COKE, TKLC, DYAX Are Seasonally Ripe To Go Up In the Next Five Weeks

^{Published on 2011-11-01 04:00:15 - WOPRAI}
 

November 1, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SYKES ENTERPRISES INC (NASDAQ:SYKE), AWARE INC/MASS (NASDAQ:AWRE), SANTARUS INC (NASDAQ:SNTS), COCA-COLA BOTTLING CO CONSOL (NASDAQ:COKE), TEKELEC (NASDAQ:TKLC), DYAX CORP (NASDAQ:DYAX) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Up:

     Symbol     Company                             Expected Return     Odds                    By The Following Date
     SYKE       SYKES ENTERPRISES INC               8.39%               81.82% (9 of 11)        Friday, November 4th 2011
     AWRE       AWARE INC/MASS                      6.47%               81.82% (9 of 11)        Thursday, November 3rd 2011
     SNTS       SANTARUS INC                        15.38%              85.71% (6 of 7)         Friday, November 11th 2011
     COKE       COCA-COLA BOTTLING CO CONSOL        9.87%               81.82% (9 of 11)        Monday, December 12th 2011
     TKLC       TEKELEC                             4.88%               90.91% (10 of 11)       Friday, November 4th 2011
     DYAX       DYAX CORP                           7.36%               100.00% (11 of 11)      Thursday, November 3rd 2011

AWARE INC/MASS (NASDAQ:AWRE) - Aware, Inc. provides products for the biometrics and Digital Subscriber Line (DSL) test industries in the United States, Germany, and internationally. It offers Biometrics Services Platform, a software platform that enables developers, integrators, and end-users to build and deploy multimodal biometric data processing solutions in support of a service-oriented architecture. The company also offers professional services to certain customers to assist in the implementation of biometrics systems. In addition, it licenses and sells software products used in various biometric functionalities, such as the enrollment of fingerprints and facial images, ID personalization and reading, and networking for criminal justice and border management in government agencies and commercial enterprises. Further, the company sells DSL test and diagnostics hardware and software products to original equipment manufacture (OEM) suppliers of DSL test equipment, including automated test-heads and handheld testers to pre-qualify, monitor, and troubleshoot DSL services. It sells its biometric software products for medical and digital imaging applications, as well as DSL test hardware and software products to telephone companies and network equipment suppliers primarily through an OEM sales channel. The company was founded in 1986 and is headquartered in Bedford, Massachusetts.

SANTARUS INC (NASDAQ:SNTS) - Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. The company commercializes CYCLOSET (bromocriptine mesylate) tablets, and focuses to commercialize GLUMETZA (metformin hydrochloride extended release tablets) that are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes. It also has a development pipeline with three late-stage product candidates in Phase III clinical programs, including ULTESA (budesonide MMX) for induction of remission of active ulcerative colitis, rifamycin SV MMX for treatment of travelers diarrhea, and RHUCIN (recombinant human C1 inhibitor) for the treatment of acute attacks of hereditary angioedema. In addition, Santarus plans to initiate a Phase I clinical study for SAN-300, an anti-VLA-1 antibody development compound that it expects to develop for the treatment of rheumatoid arthritis. The company was founded in 1996 and is based in San Diego, California.

COCA-COLA BOTTLING CO CONSOL (NASDAQ:COKE) - Coca-Cola Bottling Co. Consolidated, together with its subsidiaries, engages in the production, marketing, and distribution of nonalcoholic beverages, primarily products of The Coca-Cola Company. The company offers sparkling beverages, such as energy drinks; and still beverages, including bottled water, tea, ready-to-drink coffee, water, juices, and sports drinks. It holds cola beverage agreements and allied beverage agreements, under which it produces, distributes, and markets sparkling beverage products of The Coca-Cola Company in certain regions. The company also distributes and markets still beverages of The Coca-Cola Company, such as POWERade, vitaminwater, and Minute Maid Juices To Go, as well as produces Dasani water products under still beverage agreements. In addition, it holds agreements to produce and market Dr Pepper. Further, the company distributes and markets various other products, including Monster energy products, Cinnabon premium coffee lattes, and Sundrop, as well as its own products, such as Country Breeze tea, diet Country Breeze tea, and Tum-E Yummies, a vitamin C enhanced flavored drink. Additionally, it produces beverages for other Coca-Cola bottlers. The company sells and distributes its products directly to retail stores and other outlets, including food markets, institutional accounts, and vending machine outlets. It operates in North Carolina, South Carolina, south Alabama, South Georgia, middle Tennessee, western Virginia, and West Virginia. The company was founded in 1902 and is based in Charlotte, North Carolina.

TEKELEC (NASDAQ:TKLC) - Tekelec engages in the design, development, manufacture, marketing, sale, and support of telecommunications products and services. Its EAGLE 5 signaling platform includes Signal Transfer Point functionality for signaling system 7 (SS7) and SIGTRAN (SS7 over IP) traffic; a number portability application for number portability solutions in mobile and fixed networks, such as voice services, short message service, multimedia message services, and prepaid services; flexible routing applications for optimization of a service provider's home location register, resources, and voicemail systems; and short message routing. The companys signaling platform, EAGLE XG, consists of Service Broker application for service mediation and orchestration of current and next generation services; a SIP Signaling Router for implementation of core session initiation protocol (SIP) signaling within voice over IP and IP multimedia subsystem networks and for the call session control function; and ENUM Server application for implementation of electronic number mapping support in IP networks. The EAGLE 5 and EAGLE XG offer applications for integrated data collection used in concert with the companys Integrated Applications Solution (IAS), a real-time performance management and monitoring network application. IAS delivers monitoring plus the network visibility required to ensure that traffic is managed properly and routed in the effective manner. In addition, Tekelec provides a Mobile Messaging Product Family of applications for network-based short message service, and control of unwanted text messages. The company also offers a range of professional services, including installation and training services; and customer post-warranty support services. It sells its products through direct sales force, sales agents, partnerships, and distributor relationships worldwide. The company was founded in 1971 and is headquartered in Morrisville, North Carolina.

DYAX CORP (NASDAQ:DYAX) - Dyax Corp., a biopharmaceutical company, engages in the discovery, development, and commercialization of biotherapeutics for unmet medical needs with an emphasis on inflammatory and oncology indications. The company utilizes its proprietary drug discovery technology, known as phage display, to identify antibody, small protein, and peptide compounds for clinical development. It commercializes its lead product candidate, DX-88, a recombinant small protein, under the KALBITOR (ecallantide) name for treatment of acute attacks of hereditary angioedema in patients 16 years of age and older. The company is also developing DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals, Inc.; and for the treatment of retinal diseases in collaboration with Fovea Pharmaceuticals SA, as well as for the treatment of angiotensin converting enzyme inhibitor-induced angioedema and other angioedema indications. Its other discovery and development programs include DX-2240, an antibody that targets Tie-1 receptor on tumor blood vessels; and DX-2400 antibody, an inhibitor that inhibits matrix metalloproteinase 14 on tumor cells and tumor blood vessels. In addition, the company provides patent licenses to other biopharmaceutical and pharmaceutical companies to use its phage display patents, to discover and develop biologic compounds for use in specified fields; offers library licenses to use its phage display libraries in connection with their internal therapeutic development programs; and performs funded research for various collaborators. Further, it has co-development collaboration agreements with Athera Biotechnologies AB, Commonwealth Scientific and Industrial Research Organisation, Defiante Farmaceutica, S.A. and Syntonix Pharmaceuticals, Inc. Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641